PT  - JOURNAL ARTICLE
AU  - Wu, Danni
AU  - Goldfeld, Keith S.
AU  - Petkova, Eva
AU  - Park, Hyung G.
TI  - Improving Individualized Treatment Decisions: A Bayesian Multivariate Hierarchical Model for Developing a Treatment Benefit Index using Mixed Types of Outcomes
AID  - 10.1101/2023.11.17.23298711
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2023.11.17.23298711
4099  - http://medrxiv.org/content/early/2024/01/07/2023.11.17.23298711.short
4100  - http://medrxiv.org/content/early/2024/01/07/2023.11.17.23298711.full
AB  - Background Precision medicine has led to the development of targeted treatment strategies tailored to individual patients based on their characteristics and disease manifestations. Although precision medicine often focuses on a single health outcome for individualized treatment decision rules (ITRs), relying only on a single outcome rather than all available outcomes information leads to suboptimal data usage when developing optimal ITRs.Methods To address this limitation, we propose a Bayesian multivariate hierarchical model that leverages the wealth of correlated health outcomes collected in clinical trials. The approach jointly models mixed types of correlated outcomes, facilitating the “borrowing of information” across the multivariate outcomes, and results in a more accurate estimation of heterogeneous treatment effects compared to using single regression models for each outcome. We develop a treatment benefit index, which quantifies the relative treatment benefit of the experimental treatment over the control treatment, based on the proposed multivariate outcome model.Results We demonstrate the strengths of the proposed approach through extensive simulations and an application to an international Coronavirus Disease 2019 (COVID-19) treatment trial. Simulation results indicate that the proposed method reduces the occurrence of erroneous treatment decisions compared to a single regression model for a single health outcome. Additionally, the sensitivity analysis demonstrates the robustness of the model across various study scenarios. Application of the method to the COVID-19 trial exhibits improvements in estimating the individual-level treatment efficacy (indicated by narrower credible intervals for odds ratios) and optimal ITRs.Conclusion The study jointly models mixed types of outcomes in the context of developing ITRs. By considering multiple health outcomes, the proposed approach can advance the development of more effective and reliable personalized treatmentCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR001445.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ITRsindividualized treatment decision rulesTBItreatment benefit indexCOVID-19Coronavirus disease 2019COMPILECOntinuous Monitoring of Pooled International Trials of ConvaLEscent Plasma for COVID-19 Hospitalized PatientsRCT(s)randomized controlled trial(s)CCPCOVID-19 convalescent plasmaWHOWorld Health OrganizationHMCHamiltonian Monte Carlococumulative proportional oddsOR(s)odds ratio(s)MVNmultivariate normal distributionAUCarea under the curveROCreceiver operating characteristicPCDproportion of correct decisionsIQRinterquartile rangeSDstandard deviationCrICredible Interval